Condition: Hepatocellular Carcinoma · Organoids · Gut Microbiota · Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
A promising tool to elucidate the molecular characteristics of HCC are patient-derived organoids (PDOs), three-dimensional cultures of cells that self-organise according to tissue-specific patterns and can be used to test the susceptibility of a specific tumour to anticancer agents. In this study, PDOs for HCC will be developed that closely resemble the tumour microenvironment in vivo and mimic the crosstalk of the gut-liver axis to establish a correlation with patient prognosis and test the efficacy of available systemic therapies.
This description comes directly from the study's public registry record.
Francesca Romana Ponziani, PI · 3471227242 · francescaromana.ponziani@policlinicogemelli.it
Elisabetta Creta, SC · 3480778584 · elisabetta.creta@policlinicogemelli.it
Always discuss trial participation with your own doctor first.
| Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC CEMAD, Largo A. Gemelli, 8 | Roma, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06929845